Recaticimab Biosimilar - Research Grade

Human

PCSK9ï؟½

5mg/ml

IgG1 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

Q8NBP7

Blue ice

PCSK9 controls LDL-receptor turnover and remains a central target in cardiovascular and lipid-metabolism research. This recombinant human IgG1 kappa antibody is an unconjugated, non-therapeutic analog of recaticimab, expressed in CHO cells against human PCSK9. Released for research use only, it is purified to a low-endotoxin standard suitable for in vivo studies and supplied in scalable milligram (mg) to gram (g) quantities for high-throughput, heavy-usage laboratories. It is a reliable reagent for PCSK9-blockade assays, receptor-recycling studies, functional readouts, and preclinical models of cholesterol metabolism. Tight quality control makes it a steady reagent for high-throughput pipelines.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks